Price
Financials
Standalone, Rs crore| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Sales | 83 | 104 | 146 | 155 | 198 | 262 | 256 |
| Expenses | 72 | 81 | 111 | 120 | 161 | 216 | 217 |
| Operating Profit | 11 | 23 | 35 | 35 | 36 | 46 | 40 |
| OPM % | 13% | 22% | 24% | 23% | 18% | 18% | 15% |
| Other Income | 1 | 1 | 3 | -0 | 2 | -4 | 0 |
| Interest | 3 | 5 | 8 | 7 | 11 | 17 | 26 |
| Depreciation | 1 | 1 | 1 | 2 | 2 | 4 | 8 |
| Profit before tax | 8 | 18 | 28 | 26 | 26 | 21 | 6 |
| Tax % | 26% | 26% | 36% | 37% | 19% | 37% | 46% |
| Net Profit | 6 | 14 | 18 | 16 | 21 | 13 | 3 |
| EPS in Rs | 0.67 | 0.14 | |||||
| Dividend Payout % | 14% | 6% | 7% | 12% | 11% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 20% | 18% | -2% | ||
| Compounded Profit Growth | % | -23% | -40% | -76% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | 12% | 9% | 2% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 8 | 8 | 12 | 24 | 24 | 24 |
| Reserves | 7 | 24 | 43 | 134 | 137 | 138 | 141 |
| Borrowings | 18 | 27 | 41 | 41 | 81 | 97 | 131 |
| Other Liabilities | 17 | 22 | 34 | 38 | 40 | 33 | 38 |
| Total Liabilities | 48 | 81 | 126 | 224 | 282 | 292 | 334 |
| Fixed Assets | 14 | 21 | 22 | 27 | 43 | 94 | 94 |
| CWIP | 0 | 4 | 4 | 17 | 38 | 22 | 35 |
| Investments | 2 | 3 | 3 | 3 | 3 | 0 | 0 |
| Other Assets | 32 | 53 | 97 | 178 | 198 | 176 | 205 |
| Total Assets | 48 | 81 | 126 | 224 | 282 | 292 | 334 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -5 | 3 | -7 | -42 | 13 | 28 | -10 |
| Cash from Investing Activity | -6 | -13 | -3 | -19 | -40 | -23 | -19 |
| Cash from Financing Activity | 10 | 11 | 9 | 63 | 27 | -4 | 26 |
| Net Cash Flow | -0 | 2 | -1 | 2 | 1 | 2 | -3 |
| Free Cash Flow | -9 | -9 | -10 | -61 | -26 | 6 | -29 |
| CFO/OP | -43% | 14% | -19% | -83% | 60% | 74% | -18% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 22 | 26 | 57 | 146 | 124 | 77 | 119 |
| Inventory Days | 165 | 212 | 231 | 269 | 206 | 140 | 135 |
| Days Payable | 91 | 92 | 63 | 85 | 72 | 13 | 12 |
| Cash Conversion Cycle | 96 | 145 | 225 | 330 | 258 | 204 | 242 |
| Working Capital Days | 72 | 112 | 163 | 317 | 281 | 169 | 206 |
| ROCE % | 52% | 48% | 25% | 17% | 17% | 12% |
Fundamentals
Market Cap₹ Cr.
Current Price₹ 0.24
Book Value₹ 6.77
ROCE11.7 %
ROE2.28 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)-2%
Compounded Profit Growth (TTM)-76%
Standalone figures.
Valuation
P/E, 3-year average9.72x
P/B, 3-year average1.09x
Profitability
Operating margin (excl. other income)22.66%
Operating margin (incl. other income)22.63%
EBITDA margin22.63%
Pre-tax margin16.71%
Net profit margin10.52%
ROE16.52%
ROCE23.96%
ROA9.32%
ROE, 3-year average40.36%
ROCE, 3-year average41.44%
ROA, 3-year average15.99%
ROIC (approx.)11.49%
Tax rate37.06%
Other income / net worth-0.03%
Growth
Sales growth (latest year)6.27%
Profit growth (latest year)-9.23%
Sales CAGR, 3 years23.21%
Profit CAGR, 3 years41.91%
Per share
EPS (TTM)Rs 1.35
EPS (latest year)Rs 1.35
EPS, 3-year averageRs 13.39
Book value per shareRs 12.08
Sales per shareRs 12.85
Cash flow per shareRs -3.51
Free cash flow per shareRs -2.40
Dividend per share (latest year)Rs 0.16
Dividend per share, 3-year averageRs 0.89
Dividends
Dividend payout11.83%
Dividend payout, 3-year average8.20%
Efficiency
Asset turnover0.69x
Fixed asset turnover5.83x
Inventory turnover1.59x
Inventory days230 days
Debtor days146 days
Debtors turnover2.50x
Creditor days12 days
Cash conversion cycle242 days
Working capital days206 days
Leverage
Total debtRs 41 Cr
Cash and bankRs 4 Cr
Net debtRs 37 Cr
Debt to equity0.28x
Net debt / EBITDA1.06x
Interest coverage4.47x
Owners' fund to total sources65.07%
Debt to assets18.13%
Cash flow
Cash from Operating Activity (latest year)Rs -42 Cr
Cash from Investing Activity (latest year)Rs -19 Cr
Cash from Financing Activity (latest year)Rs 63 Cr
Net Cash Flow (latest year)Rs 2 Cr
Free cash flow (latest year)Rs -29 Cr
FCFE (approx.: FCF + change in debt)Rs -29 Cr
Cash from ops / profit, 5 years-0.25x
Statement figures
Net sales (TTM)Rs 155 Cr
Net sales (latest year)Rs 155 Cr
Operating profit excl. other income (latest year)Rs 35 Cr
Other income (TTM)Rs -0 Cr
EBITDA (TTM)Rs 35 Cr
PBDT (TTM)Rs 28 Cr
Profit before tax (TTM)Rs 26 Cr
Tax (latest year)Rs 10 Cr
Net profit (TTM)Rs 16 Cr
Net profit (latest year)Rs 16 Cr
Depreciation (TTM)Rs 2 Cr
Interest (TTM)Rs 7 Cr
Cost of goods sold (latest year)Rs 112 Cr
Total expenditure (latest year)Rs 120 Cr
Total income (latest year)Rs 155 Cr
Share capitalRs 12 Cr
ReservesRs 134 Cr
Shareholders' fundsRs 146 Cr
Total assetsRs 224 Cr
Net blockRs 27 Cr
Capital work in progressRs 17 Cr
InvestmentsRs 3 Cr
ReceivablesRs 62 Cr
InventoryRs 70 Cr
Other liabilitiesRs 38 Cr
Shares outstanding (crore)12.08
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 3 of 8| explain | Weak cash conversion Cash from operations was -96% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 26% of total assets in 2012 |
| explain | Receivables outrunning sales Receivables grew 171% vs sales +6% in 2012 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Anus Laboratories Ltd?
Anus Laboratories Ltd (532981) has a market capitalisation of Rs Cr. at the close.